Clinicopathological Characteristics and Survival of Small Cell Carcinoma of the Salivary Gland: a Population-Based Study

Figures & data

Table 1 Characteristics of 198 Patients with Small Cell Carcinoma of the Salivary Gland

Characteristics	Number
Number	198
Age (years)	72.6±12.4
Gender
Female	45
Male	153
Ethnicity
White	189
Black	4
Unknown	5
Marital status
Married	120
Single (unmarried)	13
Separated/divorced/widowed	52
Unknown	13
Pathological differentiation
Well	0
Moderate	1
Poor	45
Undifferentiated	68
Unknown	84
Summary stage
Distant	47
Regional	84
Localized	44
Unstaged	23
Laterality
Left	101
Right	91
Bilateral	2
Unknown	4
Primary site
Parotid gland	167
Submandibular gland	25
Minor salivary gland	6
Tumor stage
T1	19
T2	40
T3	22
T4	14
Unknown	103
Lymph node metastases
N0	35
N1	32
N2	39
Unknown	92
Distant metastases
Yes	14
No	93
Unknown	91
TNM stage
I	9
II	13
III	20
IV	55
Unknown	101
Surgery
Yes	130
No	65
Unknown	3
Radiation
Yes	111
No	58
Unknown	29
Chemotherapy
Yes	104
No/unknown	94

Figure 1 Overall survival for patients with SmCC of the salivary gland. (A) Overall survival for 189 patients with SmCC of the salivary gland. (B) Overall survival for patients with different SEER historic stage. (C) Overall survival for patients with different TNM stages.

Figure 2 Overall survival for patients with SmCC of the salivary gland. (A) Overall survival stratified by age. (B) Overall survival stratified by tumor stage. (C) Overall survival stratified by lymph node metastases. (D) Overall survival stratified by distant metastases.

Figure 3 The effect of treatment on overall survival for patients with SmCC of the salivary gland. (A) Surgery. (B) Radiotherapy. (C) Combination of surgery with radiotherapy. (D) Chemotherapy.

Table 2 Univariate and Multivariate Cox Proportional Hazard Analyses of Clinical Characteristics for Overall Survival Rates in Patients with SmCC of the Salivary Gland

Factor	Category	Univariate		Multivariate
HR (95% CI)	P-value	HR (95% CI)	P-value
Age (years)	≥72/<72	2.36 (1.66–3.34)	<0.01	1.81 (0.97–3.37)	0.06
Gender	Male/female	0.69 (0.48–0.99)	0.04	—	—
Race	White	Reference		—	—
	Black	1.79 (0.66–4.82)	0.25
	Other	0.79 (0.40–1.58)	0.51	—	—
Marital status	Married
	Single (unmarried)	0.88 (0.43–1.82)	0.74	3.84 (0.82–17.8)	0.09
	Separated/divorced/widowed	1.56 (1.07–2.28)	0.02	1.07 (0.54–2.12)	0.83
Pathological differentiation	Moderate/poor	Reference
	Undifferentiated	0.92 (0.60–1.42)	0.71	—	—
Summary stage	Localized	Reference
	Regional	1.78 (1.12–2.83)	0.01
	Distant	3.60 (2.16–6.01)	<0.01
Laterality	Left	Reference		Reference
	Right	0.73 (0.52–1.03)	0.07	—	—
Primary site	Parotid gland	Reference
	Submandibular gland	1.07 (0.67–1.70)	0.78
	Minor salivary gland	1.63 (0.67–3.98)	0.29
Tumor stage	T1	Reference		Reference
	T2	2.17 (1.06–4.44)	0.04	2.04 (0.94–4.43)	0.07
	T3	2.07 (0.94–4.55)	0.07	1.14 (0.44–2.93)	0.79
	T4	2.84 (1.23–6.57)	0.01	2.05 (0.74–2.65)	0.17
Lymph node metastases	N0	Reference		Reference
	N1	2.22 (1.19–4.14)	0.01	2.45 (1.13–5.32)	0.02
	N2	2.67 (1.48–4.79)	<0.01	2.53 (1.22–5.23)	0.01
Distant metastases	Yes/no	3.38 (1.81–6.30)	<0.01	2.55 (1.06–6.01)	0.03
Surgery	Yes/no	0.72 (0.51–0.98)	0.04	0.56 (0.27–1.14)	0.11
Radiation	Yes/no	0.50 (0.35–0.71)	<0.01	0.56 (0.12–0.98)	0.04
Chemotherapy	Yes/no+unknown	0.72 (0.52–0.99)	0.04	0.89 (0.67–2.09)	0.32